-

Verastem Oncology to Participate in Upcoming September Investor Conferences

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences:

  • Cantor Global Healthcare Conference in New York City: September 10, 8:35-9:05am ET
  • H.C. Wainwright Annual Global Investment Conference in New York City: September 14, 12:00-12:30 pm ET

A live webcast of the fireside chats can be accessed under “Events & Presentations” on the Company’s website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

Contacts

For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com

Industry:

Verastem Oncology

NASDAQ:VSTM
Release Versions
English

Contacts

For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com

More News From Verastem Oncology

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Vera...

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

BOSTON--(BUSINESS WIRE)--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC...

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC....
Back to Newsroom